Trial Profile

A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 With Seribantumab (MM-121), Istiratumab (MM-141), or Trametinib in Biomarker-selected Cancer Patients

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Istiratumab (Primary) ; MM-151 (Primary) ; Seribantumab (Primary) ; Trametinib (Primary)
Indications Colorectal cancer; Head and neck cancer; Lung cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Merrimack Pharmaceuticals

31 Aug 2017 Status changed from recruiting to discontinued.
07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
19 May 2016 Treatment table, drug descriptors and purpose were modified to reflect the changes presented in a Merrimack Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com